Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Return on Sales (2016 - 2025)

Historic Return on Sales for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to 0.4%.

  • Vanda Pharmaceuticals' Return on Sales fell 2900.0% to 0.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.4%, marking a year-over-year decrease of 3100.0%. This contributed to the annual value of 0.1% for FY2024, which is 1100.0% down from last year.
  • According to the latest figures from Q3 2025, Vanda Pharmaceuticals' Return on Sales is 0.4%, which was down 2900.0% from 0.52% recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Return on Sales registered a high of 0.14% during Q2 2021, and its lowest value of 0.59% during Q1 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' median Return on Sales value was 0.0% (recorded in 2023), while the average stood at 0.07%.
  • In the last 5 years, Vanda Pharmaceuticals' Return on Sales skyrocketed by 1600bps in 2023 and then plummeted by -5000bps in 2025.
  • Vanda Pharmaceuticals' Return on Sales (Quarter) stood at 0.1% in 2021, then rose by 2bps to 0.11% in 2022, then tumbled by -149bps to 0.05% in 2023, then plummeted by -75bps to 0.09% in 2024, then tumbled by -335bps to 0.4% in 2025.
  • Its last three reported values are 0.4% in Q3 2025, 0.52% for Q2 2025, and 0.59% during Q1 2025.